News - Cellvizio - Jan 26, 2023

Mauna Kea Technologies Announces Sales for the Fourth Quarter and Full Year 2022

Q4 and full year 2022 in line with expectations at €2.7 million and €7.5 million, respectively

U.S. level of sales stable in 2022 at €4.2 million despite a 60% reduction in sales personnel following the strategic realignment

$6.5 million (€6 million) cash payment from JV with Tasly received in January 2023

Mauna Kea Technologies today announces its fourth quarter and full year 2022 sales1.

"2022 was in every way in line with our expectations following the strategic realignment announced in December 2021. Despite the need to make many difficult decisions, I am proud of how the organization has responded and its commitment to Mauna Kea’s long-term success. We enter 2023 with strong sales productivity in the U.S., attractive commercial momentum in EMEA and ROW, a new strategic partnership with Tasly, a reduced cash burn rate and stable liquidity position, and most importantly, a more disciplined and efficient global organization.” said Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies. “Based on the increasing confidence that market demand for Cellvizio’s proprietary visualization technology is accelerating, we remain committed to leveraging our technological platform to provide high value-added clinical solutions to our customers and partners.”

​​​​For additional details and financial results, please see the full press release.

[1] Sales released to date strictly relate to sales of consumables, systems and services.